Sign in with Google. Opens in new tab
ENTITY
SMARTSCORE: 3/5
Shanghai Junshi Biosciences

Shanghai Junshi Biosciences (1877 HK)

250
Analysis
Health CareChina
Shanghai Junshi Biosciences Co., Ltd. operates as a biopharmaceutical company. The Company develops and sells small molecule drugs, antibody drug conjugates, and other products. Shanghai Junshi Biosciences markets its products worldwide.
more
16 Jun 2025 00:30

Shanghai Junshi Bioscience (1877 HK): Placement Good, A Long Term Bet for Sure

​Shanghai Junshi is raising funds through 41M H share placement to support drug development and replenishment of working capital. Lower R&D...

Logo
243 Views
Share
29 Apr 2025 13:32

Shanghai Junshi Bioscience (1877 HK): Tuoyi Gains Momentum; Losses Narrow; New Geographies Open Up

​Shanghai Junshi Biosciences sees 32% revenue growth in 1Q25, driven by toripalimab in China. Loss narrowed to RMB 239M in 1Q25 from RMB 307M in...

Logo
271 Views
Share
16 Jan 2025 15:02

Shanghai Junshi Bioscience (1877 HK): Key Drug on High Trajectory; Geopolitical Tension Spoils Party

​Shanghai Junshi Biosciences sees strong revenue growth for toripalimab in China. While US launch of the drug was in-line, geopolitical tensions...

Logo
420 Views
Share
13 Apr 2023 01:12

[Junshi Biosciences (1877 HK) TP Change]: Medium to near Term Outlook Is Still Cloudy at Best

We continue to view JUNSHI’s Phase III pipeline, consisting of Senaparib (JS109/IMP4297)(PARP), Ongericimab (JS002)(PCSK9), Bevacizumab...

Share
07 Jul 2024 01:19

China Healthcare Weekly (July.7) - MNCs' Next Move In Licensing Deals, Topchoice, Junshi's Trouble

​Investors should wait to see MNCs' next move before deciding on licensing deals. Topchoice's growth is positive but unit price per customer may...

Logo
514 Views
Share
x